- Home
- IMAB vs TMCI Comparison
IMAB vs TMCI Comparison
Compare IMAB & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- TMCI
- Stock Information
- Founded
- IMAB 2014
- TMCI 2014
- Country
- IMAB United States
- TMCI United States
- Employees
- IMAB N/A
- TMCI N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IMAB Health Care
- TMCI Health Care
- Exchange
- IMAB Nasdaq
- TMCI Nasdaq
- Market Cap
- IMAB 486.4M
- TMCI 401.8M
- IPO Year
- IMAB 2020
- TMCI 2021
- Fundamental
- Price
- IMAB $4.70
- TMCI $6.85
- Analyst Decision
- IMAB Strong Buy
- TMCI Hold
- Analyst Count
- IMAB 6
- TMCI 5
- Target Price
- IMAB $7.50
- TMCI $8.40
- AVG Volume (30 Days)
- IMAB 2.2M
- TMCI 256.7K
- Earning Date
- IMAB 11-14-2025
- TMCI 11-06-2025
- Dividend Yield
- IMAB N/A
- TMCI N/A
- EPS Growth
- IMAB N/A
- TMCI N/A
- EPS
- IMAB N/A
- TMCI N/A
- Revenue
- IMAB N/A
- TMCI $213,751,000.00
- Revenue This Year
- IMAB N/A
- TMCI $10.63
- Revenue Next Year
- IMAB N/A
- TMCI $9.43
- P/E Ratio
- IMAB N/A
- TMCI N/A
- Revenue Growth
- IMAB N/A
- TMCI 7.67
- 52 Week Low
- IMAB $0.60
- TMCI $4.54
- 52 Week High
- IMAB $6.79
- TMCI $10.79
- Technical
- Relative Strength Index (RSI)
- IMAB 49.60
- TMCI 57.80
- Support Level
- IMAB $4.13
- TMCI $6.65
- Resistance Level
- IMAB $6.79
- TMCI $7.08
- Average True Range (ATR)
- IMAB 0.72
- TMCI 0.31
- MACD
- IMAB -0.14
- TMCI 0.09
- Stochastic Oscillator
- IMAB 21.43
- TMCI 82.31
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.